Advisors Asset Management, Inc. Iovance Biotherapeutics, Inc. Transaction History

Advisors Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$5.53 - $8.22 $1,111 - $1,652	-201 Reduced 4.85%	3,941 $24,000
Q3 2022 Nov 08, 2022	SELL	$9.53 - $13.11 $40,702 - $55,992	-4,271 Reduced 9.0%	43,168 $414,000
Q2 2022 Aug 08, 2022	SELL	$6.38 - $18.33 $63,053 - $181,155	-9,883 Reduced 17.24%	47,439 $524,000
Q1 2022 May 17, 2022	SELL	$12.38 - $19.1 $443,761 - $684,639	-35,845 Reduced 38.47%	57,322 $954,000
Q4 2021 Feb 15, 2022	SELL	$16.55 - $27.63 $26,662 - $44,511	-1,611 Reduced 1.7%	93,167 $1.78 Million
Q3 2021 Nov 12, 2021	BUY	$20.35 - $26.63 $28,225 - $36,935	1,387 Added 1.49%	94,778 $2.34 Million
Q2 2021 Jul 30, 2021	BUY	$16.33 - $33.07 $268,334 - $543,406	16,432 Added 21.35%	93,391 $2.43 Million
Q1 2021 May 07, 2021	BUY	$28.67 - $52.59 $1.01 Million - $1.86 Million	35,396 Added 85.16%	76,959 $2.44 Million
Q4 2020 Feb 12, 2021	BUY	$28.04 - $50.26 $1.01 Million - $1.82 Million	36,130 Added 665.01%	41,563 $1.93 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $69,846 - $91,367	2,517 Added 86.32%	5,433 $179,000
Q2 2020 Aug 12, 2020	BUY	$27.21 - $41.0 $79,344 - $119,556	2,916 New	2,916 $80,000

339

247M

2.51M

3.5M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $877M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.